Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials

<p>Abstract</p> <p>Background</p> <p>Although interim analysis approaches in clinical trials are widely known, information on current practice of planned monitoring is still scarce. Reports of studies rarely include details on the strategies for both data monitoring and...

Full description

Bibliographic Details
Main Authors: De Rosa Marisa, Torri Valter, Albertazzi Elena, Rotmensz Nicole, Floriani Irene, Tomino Carlo, de Braud Fillipo
Format: Article
Language:English
Published: BMC 2008-07-01
Series:Trials
Online Access:http://www.trialsjournal.com/content/9/1/46
_version_ 1818238101084962816
author De Rosa Marisa
Torri Valter
Albertazzi Elena
Rotmensz Nicole
Floriani Irene
Tomino Carlo
de Braud Fillipo
author_facet De Rosa Marisa
Torri Valter
Albertazzi Elena
Rotmensz Nicole
Floriani Irene
Tomino Carlo
de Braud Fillipo
author_sort De Rosa Marisa
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Although interim analysis approaches in clinical trials are widely known, information on current practice of planned monitoring is still scarce. Reports of studies rarely include details on the strategies for both data monitoring and interim analysis. The aim of this project is to investigate the forms of monitoring used in cancer clinical trials and in particular to gather information on the role of interim analyses in the data monitoring process of a clinical trial. This study focused on the prevalence of different types of interim analyses and data monitoring in cancer clinical trials.</p> <p>Methods</p> <p>Source of investigation were the protocols of cancer clinical trials included in the Italian registry of clinical trials from 2000 to 2005. Evaluation was restricted to protocols of randomised studies with a time to event endpoint, such as overall survival (OS) or progression free survival (PFS). A template data extraction form was developed and tested in a pilot phase. Selection of relevant protocols and data extraction were performed independently by two evaluators, with differences in the data assessment resolved by consensus with a third reviewer, referring back to the original protocol. Information was obtained on a) general characteristics of the protocol b) disease localization and patient setting; c) study design d) interim analyses; e) DSMC.</p> <p>Results</p> <p>The analysis of the collected protocols reveals that 70.7% of the protocols incorporate statistical interim analysis plans, but only 56% have also a DSMC and be considered adequately planned. The most concerning cases are related to lack of any form of monitoring (20.0% of the protocols), and the planning of interim analysis, without DSMC (14.7%).</p> <p>Conclusion</p> <p>The results indicate that there is still insufficient attention paid to the implementation of interim analysis.</p>
first_indexed 2024-12-12T12:36:18Z
format Article
id doaj.art-2b298d53b13644939b8f9843e7fcf024
institution Directory Open Access Journal
issn 1745-6215
language English
last_indexed 2024-12-12T12:36:18Z
publishDate 2008-07-01
publisher BMC
record_format Article
series Trials
spelling doaj.art-2b298d53b13644939b8f9843e7fcf0242022-12-22T00:24:20ZengBMCTrials1745-62152008-07-01914610.1186/1745-6215-9-46Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical TrialsDe Rosa MarisaTorri ValterAlbertazzi ElenaRotmensz NicoleFloriani IreneTomino Carlode Braud Fillipo<p>Abstract</p> <p>Background</p> <p>Although interim analysis approaches in clinical trials are widely known, information on current practice of planned monitoring is still scarce. Reports of studies rarely include details on the strategies for both data monitoring and interim analysis. The aim of this project is to investigate the forms of monitoring used in cancer clinical trials and in particular to gather information on the role of interim analyses in the data monitoring process of a clinical trial. This study focused on the prevalence of different types of interim analyses and data monitoring in cancer clinical trials.</p> <p>Methods</p> <p>Source of investigation were the protocols of cancer clinical trials included in the Italian registry of clinical trials from 2000 to 2005. Evaluation was restricted to protocols of randomised studies with a time to event endpoint, such as overall survival (OS) or progression free survival (PFS). A template data extraction form was developed and tested in a pilot phase. Selection of relevant protocols and data extraction were performed independently by two evaluators, with differences in the data assessment resolved by consensus with a third reviewer, referring back to the original protocol. Information was obtained on a) general characteristics of the protocol b) disease localization and patient setting; c) study design d) interim analyses; e) DSMC.</p> <p>Results</p> <p>The analysis of the collected protocols reveals that 70.7% of the protocols incorporate statistical interim analysis plans, but only 56% have also a DSMC and be considered adequately planned. The most concerning cases are related to lack of any form of monitoring (20.0% of the protocols), and the planning of interim analysis, without DSMC (14.7%).</p> <p>Conclusion</p> <p>The results indicate that there is still insufficient attention paid to the implementation of interim analysis.</p>http://www.trialsjournal.com/content/9/1/46
spellingShingle De Rosa Marisa
Torri Valter
Albertazzi Elena
Rotmensz Nicole
Floriani Irene
Tomino Carlo
de Braud Fillipo
Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
Trials
title Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
title_full Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
title_fullStr Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
title_full_unstemmed Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
title_short Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
title_sort approaches to interim analysis of cancer randomised clinical trials with time to event endpoints a survey from the italian national monitoring centre for clinical trials
url http://www.trialsjournal.com/content/9/1/46
work_keys_str_mv AT derosamarisa approachestointerimanalysisofcancerrandomisedclinicaltrialswithtimetoeventendpointsasurveyfromtheitaliannationalmonitoringcentreforclinicaltrials
AT torrivalter approachestointerimanalysisofcancerrandomisedclinicaltrialswithtimetoeventendpointsasurveyfromtheitaliannationalmonitoringcentreforclinicaltrials
AT albertazzielena approachestointerimanalysisofcancerrandomisedclinicaltrialswithtimetoeventendpointsasurveyfromtheitaliannationalmonitoringcentreforclinicaltrials
AT rotmensznicole approachestointerimanalysisofcancerrandomisedclinicaltrialswithtimetoeventendpointsasurveyfromtheitaliannationalmonitoringcentreforclinicaltrials
AT florianiirene approachestointerimanalysisofcancerrandomisedclinicaltrialswithtimetoeventendpointsasurveyfromtheitaliannationalmonitoringcentreforclinicaltrials
AT tominocarlo approachestointerimanalysisofcancerrandomisedclinicaltrialswithtimetoeventendpointsasurveyfromtheitaliannationalmonitoringcentreforclinicaltrials
AT debraudfillipo approachestointerimanalysisofcancerrandomisedclinicaltrialswithtimetoeventendpointsasurveyfromtheitaliannationalmonitoringcentreforclinicaltrials